 |
|||
|
Novel cancer drugs (phase II) based on "gene silencing" concept with a proprietary RNA antagonist platform. 367m€ first licensing deal in 2006
Santaris Pharma A/S is a clinical-stage biopharmaceutical company focussed on developing next generation RNA-silencing drugs based on its proprietary LNA® (Locked Nucleic Acid) technology for the treatment of cancer, metabolic disorders and other serious diseases. The Company’s drug pipeline is comprised of novel RNA Antagonist drugs based on its unique LNA® chemistry. LNA drugs, with their high potency and biostability, have the potential to transform the field of RNA inhibiting therapeutics, making specific and effective gene silencing a reality in human medicine. If this potential is realised, even in part, it may be possible to design new drugs to treat a wide variety of human diseases by switching off the expression of harmful genes. Santaris Pharma holds the world wide patent rights to the exploitation of LNA in pharmaceuticals. Presently three drugs are in preclinical or clinical development. The lead drug candidate, SPC2996, is currently undergoing an international, multicentric, phase I/II clinical study in Chronic Lymphocytic Leukemia (CLL). |
News :
12/30/2009 New data show breakthrough microRNA-targeted therapy developed using Santaris Pharma A/S proprietary LNA technology holds promise as new treatment for Hepatitis C
09/04/2009 Santaris Pharma A/S forms strategic alliance with Shire plc to develop RNA-based medicines for the treatment of rare genetic disorders
01/13/2009 Santaris Pharma announce the signing of a strategic alliance with Wyeth, for the discovery and development of RNA-based drugs
06/18/2008 Santaris Pharma appoints Søren Tulstrup as new President & CEO
05/15/2008 Santaris Pharma receives a 6mEUR grant from the Danish Advanced Technology Foundation
01/03/2008 Seventure Partners, one of the most active foreign investors in Scandinavia and the only French shareholder in Danish company Santaris Pharma, is pleased to announce the signature of a major R&D agreement with GlaxoSmithKline
01/03/2008 Seventure Partners, the only French shareholder in Danish company Santaris Pharma, is pleased to announce additional financing of €20,4 million (US$30 million)
|
||
